retatrutide rx Retatrutide: The New Triple-Agonist Weight Loss Treatment Extreme Side Effects Followed Overdose

10.1016/j.pneurobio.2015.02.001 Prog

Based on major clinical trials, patients typically achieve an average weight reduction of 15% to 20% of their initial body weight when the medication is consistently combined with a comprehensive lifestyle program

Patients need to self-inject twice daily, which may prove inconvenient and hinder consistent use

Minor, but unmistakable

**Credit for NASW (National Association of Social Workers) is not available for this presentation** Description of Presentation: The rise in GLP-1 agonists consumers as well as expanding indication for use is now spreading more and more into the realm of eating disorders